Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17790862 | 1.00 | CNR1 (0.45) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL17790888 | 1.00 | CNR1 (0.45) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL17790883 | 0.88 | CNR1 (0.43) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL17793933 | 0.88 | CNR1 (0.43) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL17790864 | 0.86 | CNR1 (0.41) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL19640727 | 0.83 | ALDH1A1 (0.44) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL19640729 | 0.83 | ALDH1A1 (0.44) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL12685098 | 0.82 | CNR1 (0.56) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL19343063 | 0.81 | CNR1 (0.52) | CNR1ALDH1A1MAPTFAAHALOX12 | |
| SCHEMBL19343065 | 0.81 | CNR1 (0.52) | CNR1ALDH1A1MAPTFAAHALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | CNR1 2351/4885ALDH1A1 1342/4885MAPT 1528/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | CNR1 2707/4885ALDH1A1 1672/4885MAPT 1391/4885 |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | ATG7, ATG4A, SLC27A1 | CNR1 1147/4885ALDH1A1 2685/4885MAPT 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.